FDA Approves Bispecific for Advanced Bile Duct Cancer
Bispecific antibodies surge as next-gen oncology innovation accelerates
BioNTech faces pivotal moment with dual cancer datasets shaping pipeline trajectory
Yzybio-B advances CD3/EpCAM bispecific M701 with new clinical data readouts
Novel oncology candidates expand pipeline momentum across solid tumour targets
7-9 July, 2026 | London UK